Cole

Abstract 5457: Cytarabine leaves a mutational fingerprint in relapsing leukemia

*Cancer Research* 2014; 74(Suppl 19):5457

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia

*Leukemia* 2015; 29(2):491-494

Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer

*Clinical Pharmacokinetics* 2014; 53(8):741-751

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

*Journal of Hepatology* 2014; 60(1):110-117

Population pharmacokinetic investigation of actinomycin-D in children and young adults

*The Journal of Clinical Pharmacology* 2008; 48(1):35-42

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma

*Clinical Cancer Research* 2013; 19(2):469-479

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

*Acta Neuropathologica* 2012; 123(4):501-513

Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients

*Pediatric Blood & Cancer* 2011; 57(5):705-897

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy

*European Journal of Cancer* 2011; 47(10):1556-1563

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers

*Biochem J* 2011; 436(3):671-679